Skip to content
DataLookout
Menu

TL-SBRT-nccRCCNCT07922928

Toripalimab and Lenvatinib With or Without SBRT Before Surgery for Non-Clear Cell Kidney Cancer

StatusNot Yet Recruiting
PhasePhase 2
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 1 version: 1 with changes below.

  1. Study First Submitted

Endpoints

Primary

Tumor Cell Necrosis Rate (TCNR)
Timeframe: At surgery following neoadjuvant treatment, approximately 5 to 6 months after the first dose.

Secondary (4)

R0 Resection Rate
Objective Response Rate (ORR)
Disease Control Rate (DCR)
Major Pathological Response (MPR) Rate

Arms and interventions

Toripalimab Plus LenvatinibActive comparator

Toripalimab 240 mg intravenously every 3 weeks plus lenvatinib 12 mg orally once daily for six 21-day cycles, followed by surgery.

Toripalimab Plus Lenvatinib and SBRTExperimental

Toripalimab 240 mg intravenously every 3 weeks plus lenvatinib 12 mg orally once daily for six 21-day cycles. SBRT at 40 Gy in five fractions is delivered to the primary renal tumor after cycle 2 and before cycle 4, followed by surgery.

Drugs: Toripalimab, Lenvatinib

Radiation: Stereotactic Body Radiotherapy